MAPT and Alzheimer disease: High‐sensitivity assays for plasma phosphorylated tau (p‐tau) protein achieve sensitivity and specificity > 90% for AD pathology27, 28 and may be altered when there is AD co‐pathology in LBD (as shown previously in a sample from this cohort29 and independent studies30).